Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitors with Chemoradiotherapy in Lung Metastatic NPC
NCT07062484Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Trial of tislelizumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective Response Rate at 3 months. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07062484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07062484.